SCHEMBL8097425

SCHEMBL8097425

CC(C)(C)OC(=O)c1ccc(-c2ccc(N)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.66
CA1 P00915 3/20 0.66
CA2 P00918 3/20 0.66
CA9 Q16790 3/20 0.66
CA14 Q9ULX7 3/20 0.66
CYP3A4 P08684 3/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
MAOA P21397 2/20 0.50
TSHR P16473 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
PDE4D Q08499 1/20 0.45
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
ADRB3 P13945 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
PHLPP2 Q6ZVD8 1/20 0.44
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380152 0.94 CA12 (0.57) CA12CA1CA2CA9CA14
Methane SCHEMBL28278848 0.92 CA12 (0.56) CA12CA1CA2CA9CA14
Nitrogen SCHEMBL27824368 0.91 CA12 (0.54) CA12CA1CA2CA9CA14
SCHEMBL6350965 0.90 CA12 (0.71) CA12CA1CA2CA9CA14
Acetic Acid SCHEMBL5239675 0.89 CA12 (0.53) CA12CA1CA2CA9CA14
SCHEMBL2076830 0.85 CA12 (0.65) CA12CA1CA2CA9CA14
Formic Acid Methyl Ester SCHEMBL28278877 0.84 CA12 (0.49) CA12CA1CA2CA9CA14
Hydrazine SCHEMBL10771056 0.84 CA12 (0.62) CA12CA1CA2CA9CA14
SCHEMBL109451 0.84 CA1 (0.61) CA12CA1CA2CA9CA14
SCHEMBL8097492 0.84 CA12 (0.49) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695226-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2026-02-18 EP disclosed
US-20240366598-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2024-11-07 US disclosed
WO-2024214038-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2024-10-17 WO disclosed
US-6011175-A Inhibition of farnesyltransferase UNIVERSITY OF PITTSBURGH (US) 2000-01-04 US disclosed
US-5965539-A PEPTIDOMIMETICS; ANTI-CANCER DRUGS UNIVERISTY OF PITTSBURGH (US) 1999-10-12 US disclosed
EP-0794789-A4 INHIBITORS OF PRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-05-26 EP disclosed
US-5705686-A 3-MERCAPTO-2-AMINO-PROPYLAMINOBIPHENYL DERIVATIVES; PEPTIDOMIMETICS; ANTICARCINOGENIC AGENTS UNIVERSITY OF PITTSBURGH (US) 1998-01-06 US disclosed
EP-0794789-A1 INHIBITORS OF PRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-09-17 EP disclosed
WO-1996021456-A1 INHIBITORS OF PRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366598-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF GIPR, GLP1R, GPR119 CA12 3264/4885CA1 2418/4885CA2 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.